Intraocular penetration of tamoxifen

Christina Flaxel, Bridget Mulholland, Benjamin Haynes, Zdenek J. Gregor

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: To document ocular penetration of oral tamoxifen in patients being administered systemic therapy by measuring intraocular and serum levels of the drug in a series of patients undergoing elective ocular surgery. Design: Nonrandomized, prospective, comparative trial. Participants: Twenty-one eyes of 21 patients undergoing elective ocular surgery (cataract extraction or vitrectomy). Twenty patients were using the antiestrogen, tamoxifen, and one participant was not. Nine patients were excluded in the final analysis because of inadequate sample size. Intervention: Preoperative serum samples and perioperative aqueous samples, vitreous samples, or both were obtained for each patient, and these were analyzed for tamoxifen and its metabolites. Dilated fundus examination was performed before surgery on all patients. Main Outcome Measures: Evidence of tamoxifen, its metabolites, or both in the samples. Results: Tamoxifen was detected in all analyzed serum samples (range, 82.4-290.0 ng/ml.) from patients taking the medication and was found to have penetrated into both vitreous (range, 0.5-7.8 ng/ml) and aqueous (range, 0.5-3.9 ng/ml) cavities. No relationship was found between serum and intraocular levels. Conclusions: This study shows that tamoxifen penetrates intraocular fluids to varying degrees. The drug levels in aqueous and vitreous do not appear to correlate with serum levels. Evidence of tamoxifen retinopathy or keratopathy was not seen. (C) 2000 by the American Academy of Ophthalmology.

Original languageEnglish (US)
Pages (from-to)2006-2009
Number of pages4
JournalOphthalmology
Volume107
Issue number11
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Tamoxifen
Serum
Estrogen Receptor Modulators
Cataract Extraction
Aqueous Humor
Vitrectomy
Pharmaceutical Preparations
Sample Size
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Flaxel, C., Mulholland, B., Haynes, B., & Gregor, Z. J. (2000). Intraocular penetration of tamoxifen. Ophthalmology, 107(11), 2006-2009. https://doi.org/10.1016/S0161-6420(00)00364-X

Intraocular penetration of tamoxifen. / Flaxel, Christina; Mulholland, Bridget; Haynes, Benjamin; Gregor, Zdenek J.

In: Ophthalmology, Vol. 107, No. 11, 2000, p. 2006-2009.

Research output: Contribution to journalArticle

Flaxel, C, Mulholland, B, Haynes, B & Gregor, ZJ 2000, 'Intraocular penetration of tamoxifen', Ophthalmology, vol. 107, no. 11, pp. 2006-2009. https://doi.org/10.1016/S0161-6420(00)00364-X
Flaxel, Christina ; Mulholland, Bridget ; Haynes, Benjamin ; Gregor, Zdenek J. / Intraocular penetration of tamoxifen. In: Ophthalmology. 2000 ; Vol. 107, No. 11. pp. 2006-2009.
@article{5310968f864c4917862de0a6176675da,
title = "Intraocular penetration of tamoxifen",
abstract = "Objective: To document ocular penetration of oral tamoxifen in patients being administered systemic therapy by measuring intraocular and serum levels of the drug in a series of patients undergoing elective ocular surgery. Design: Nonrandomized, prospective, comparative trial. Participants: Twenty-one eyes of 21 patients undergoing elective ocular surgery (cataract extraction or vitrectomy). Twenty patients were using the antiestrogen, tamoxifen, and one participant was not. Nine patients were excluded in the final analysis because of inadequate sample size. Intervention: Preoperative serum samples and perioperative aqueous samples, vitreous samples, or both were obtained for each patient, and these were analyzed for tamoxifen and its metabolites. Dilated fundus examination was performed before surgery on all patients. Main Outcome Measures: Evidence of tamoxifen, its metabolites, or both in the samples. Results: Tamoxifen was detected in all analyzed serum samples (range, 82.4-290.0 ng/ml.) from patients taking the medication and was found to have penetrated into both vitreous (range, 0.5-7.8 ng/ml) and aqueous (range, 0.5-3.9 ng/ml) cavities. No relationship was found between serum and intraocular levels. Conclusions: This study shows that tamoxifen penetrates intraocular fluids to varying degrees. The drug levels in aqueous and vitreous do not appear to correlate with serum levels. Evidence of tamoxifen retinopathy or keratopathy was not seen. (C) 2000 by the American Academy of Ophthalmology.",
author = "Christina Flaxel and Bridget Mulholland and Benjamin Haynes and Gregor, {Zdenek J.}",
year = "2000",
doi = "10.1016/S0161-6420(00)00364-X",
language = "English (US)",
volume = "107",
pages = "2006--2009",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Intraocular penetration of tamoxifen

AU - Flaxel, Christina

AU - Mulholland, Bridget

AU - Haynes, Benjamin

AU - Gregor, Zdenek J.

PY - 2000

Y1 - 2000

N2 - Objective: To document ocular penetration of oral tamoxifen in patients being administered systemic therapy by measuring intraocular and serum levels of the drug in a series of patients undergoing elective ocular surgery. Design: Nonrandomized, prospective, comparative trial. Participants: Twenty-one eyes of 21 patients undergoing elective ocular surgery (cataract extraction or vitrectomy). Twenty patients were using the antiestrogen, tamoxifen, and one participant was not. Nine patients were excluded in the final analysis because of inadequate sample size. Intervention: Preoperative serum samples and perioperative aqueous samples, vitreous samples, or both were obtained for each patient, and these were analyzed for tamoxifen and its metabolites. Dilated fundus examination was performed before surgery on all patients. Main Outcome Measures: Evidence of tamoxifen, its metabolites, or both in the samples. Results: Tamoxifen was detected in all analyzed serum samples (range, 82.4-290.0 ng/ml.) from patients taking the medication and was found to have penetrated into both vitreous (range, 0.5-7.8 ng/ml) and aqueous (range, 0.5-3.9 ng/ml) cavities. No relationship was found between serum and intraocular levels. Conclusions: This study shows that tamoxifen penetrates intraocular fluids to varying degrees. The drug levels in aqueous and vitreous do not appear to correlate with serum levels. Evidence of tamoxifen retinopathy or keratopathy was not seen. (C) 2000 by the American Academy of Ophthalmology.

AB - Objective: To document ocular penetration of oral tamoxifen in patients being administered systemic therapy by measuring intraocular and serum levels of the drug in a series of patients undergoing elective ocular surgery. Design: Nonrandomized, prospective, comparative trial. Participants: Twenty-one eyes of 21 patients undergoing elective ocular surgery (cataract extraction or vitrectomy). Twenty patients were using the antiestrogen, tamoxifen, and one participant was not. Nine patients were excluded in the final analysis because of inadequate sample size. Intervention: Preoperative serum samples and perioperative aqueous samples, vitreous samples, or both were obtained for each patient, and these were analyzed for tamoxifen and its metabolites. Dilated fundus examination was performed before surgery on all patients. Main Outcome Measures: Evidence of tamoxifen, its metabolites, or both in the samples. Results: Tamoxifen was detected in all analyzed serum samples (range, 82.4-290.0 ng/ml.) from patients taking the medication and was found to have penetrated into both vitreous (range, 0.5-7.8 ng/ml) and aqueous (range, 0.5-3.9 ng/ml) cavities. No relationship was found between serum and intraocular levels. Conclusions: This study shows that tamoxifen penetrates intraocular fluids to varying degrees. The drug levels in aqueous and vitreous do not appear to correlate with serum levels. Evidence of tamoxifen retinopathy or keratopathy was not seen. (C) 2000 by the American Academy of Ophthalmology.

UR - http://www.scopus.com/inward/record.url?scp=0033767452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033767452&partnerID=8YFLogxK

U2 - 10.1016/S0161-6420(00)00364-X

DO - 10.1016/S0161-6420(00)00364-X

M3 - Article

C2 - 11054323

AN - SCOPUS:0033767452

VL - 107

SP - 2006

EP - 2009

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 11

ER -